奥浦迈股价涨5%，工银瑞信基金旗下1只基金位居十大流通股东，持有330.01万股浮盈赚取924.02万元

Group 1 - The core viewpoint of the news is that Aopumai's stock price increased by 5% to 58.80 CNY per share, with a trading volume of 30.88 million CNY and a turnover rate of 0.47%, resulting in a total market capitalization of 6.693 billion CNY [1] - Aopumai Biotechnology Co., Ltd. is located in Shanghai and was established on November 27, 2013, with its listing date on September 2, 2022. The company's main business involves cell culture products and services [1] - The revenue composition of Aopumai is primarily from products (87.34%), followed by services (12.53%) and other sources (0.13%) [1] Group 2 - Among Aopumai's top ten circulating shareholders, a fund under ICBC Credit Suisse Asset Management holds a significant position. The fund, ICBC Frontier Medical Stock A (001717), increased its holdings by 400,000 shares, totaling 3.3001 million shares, which represents 2.91% of the circulating shares [2] - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, with a current scale of 9.636 billion CNY. Year-to-date returns are 21.28%, ranking 2685 out of 4216 in its category, while the one-year return is 12.68%, ranking 2778 out of 3917 [2] - The fund manager, Zhao Bei, has a tenure of 10 years and 361 days, with total assets under management of 17.223 billion CNY. The best fund return during Zhao's tenure is 219.1%, while the worst return is -31.76% [2]